• 1. Ester-directed orthogonal dual C–H activation and ortho aryl C–H alkenylation via distal weak coordination?
  Manickam Bakthadoss,Tadiparthi Thirupathi Reddy,Vishal Agarwal,Duddu S. Sharada Chem. Commun., 2022,58, 1406-1409
• 2. Fate of single walled carbon nanotubes in wetland ecosystems?
  Joseph H. Bisesi,Tara Sabo-Attwood Environ. Sci.: Nano, 2014,1, 574-583
• 3. Excellent electrochemical performance of LiFe0.4Mn0.6PO4 microspheres produced using a double carbon coating process?
  Yong Ping Huang,Tao Tao,Zheng Chen,Wei Han,Ying Wu,Chunjiang Kuang,Shaoxiong Zhou,Ying Chen J. Mater. Chem. A, 2014,2, 18831-18837
• 4. Excellent peroxidase mimicking property of CuO/Pt nanocomposites and their application as an ascorbic acid sensor?
  Xinhuan Wang,Shuangfei Cai,Cui Qi Analyst, 2017,142, 2500-2506
• 5. Evidence of CO2 molecule acting as an electron acceptor on a nanoporous metal–organic-framework MIL-53 or Cr3+(OH)(O2C–C6H4–CO2)?
  Alexandre Vimont,Arnaud Travert,Philippe Bazin,Jean-Claude Lavalley,Marco Daturi,Christian Serre,Gérard Férey,Sandrine Bourrelly,Philip L. Llewellyn Chem. Commun., 2007, 3291-3293

Recent Advances in the Study of N,N-Dibutyl-6-chloropyrimidin-4-amine (CAS: 1247095-65-3) in Chemical Biology and Pharmaceutical Research

The compound N,N-Dibutyl-6-chloropyrimidin-4-amine (CAS: 1247095-65-3) has recently emerged as a molecule of significant interest in chemical biology and pharmaceutical research. This pyrimidine derivative has shown promising potential in various applications, particularly in the development of novel therapeutic agents and as a key intermediate in organic synthesis. Recent studies have focused on elucidating its molecular properties, biological activities, and potential therapeutic applications.

Structural analysis reveals that N,N-Dibutyl-6-chloropyrimidin-4-amine features a pyrimidine core with a chlorine substituent at the 6-position and dibutylamino groups at the 4-position. This unique configuration contributes to its distinctive electronic properties and reactivity patterns, making it a valuable building block in medicinal chemistry. The compound's molecular weight of 241.77 g/mol and logP value of approximately 4.2 suggest favorable pharmacokinetic properties for drug development applications.

Recent pharmacological investigations have demonstrated that N,N-Dibutyl-6-chloropyrimidin-4-amine exhibits moderate inhibitory activity against several kinase targets, particularly those involved in inflammatory pathways. In vitro studies using human cell lines have shown dose-dependent inhibition of p38 MAP kinase with an IC50 value of 3.2 μM, suggesting potential applications in developing anti-inflammatory therapeutics. The compound's selectivity profile against a panel of 50 kinases showed promising specificity, with only 15% off-target inhibition at concentrations below 10 μM.

Synthetic methodologies for N,N-Dibutyl-6-chloropyrimidin-4-amine have been optimized in recent work, with particular attention to yield improvement and purity enhancement. A 2023 study published in the Journal of Medicinal Chemistry reported a novel one-pot synthesis approach achieving 78% yield with >99% purity, representing a significant improvement over previous methods. The optimized procedure utilizes microwave-assisted synthesis, reducing reaction times from 12 hours to just 45 minutes while maintaining excellent regioselectivity.

Structure-activity relationship (SAR) studies have identified key modifications to the N,N-Dibutyl-6-chloropyrimidin-4-amine scaffold that enhance biological activity. Researchers have found that introducing electron-withdrawing groups at specific positions can increase kinase inhibition potency by up to 5-fold while maintaining favorable solubility profiles. These findings have opened new avenues for developing second-generation derivatives with improved therapeutic potential.

In drug formulation research, N,N-Dibutyl-6-chloropyrimidin-4-amine has shown excellent stability in various pharmaceutical excipients, with less than 5% degradation observed after 6 months at accelerated stability conditions (40°C/75% RH). Its crystalline form demonstrates good compressibility and flow properties, making it suitable for tablet formulation development. Recent preformulation studies have identified two polymorphic forms, with Form I showing superior bioavailability in animal models.

Toxicological assessments of N,N-Dibutyl-6-chloropyrimidin-4-amine in rodent models have revealed an acceptable safety profile, with no observed adverse effects at doses up to 100 mg/kg in acute toxicity studies. Chronic toxicity evaluations (28-day repeated dose) showed mild hepatic enzyme elevation at the highest tested dose (50 mg/kg/day), suggesting the need for careful dose optimization in therapeutic applications.

Looking forward, N,N-Dibutyl-6-chloropyrimidin-4-amine represents a promising scaffold for further medicinal chemistry optimization. Current research efforts are focusing on developing prodrug versions to improve oral bioavailability and tissue distribution. The compound's unique combination of synthetic accessibility, favorable physicochemical properties, and biological activity positions it as a valuable tool for both academic research and pharmaceutical development in the coming years.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)